CHARGED ALPHATMFrontier AI stock research

PEN · NYSE

Penumbra Inc

Medical Devices · United States

USD 317.560.1% daily changeQuote 2026-10-06 · USD
Market cap (USD)
US$12.51B
Trailing P/E
78.02x
Forward P/E
51.79x
Quarterly revenue growth
14.9%
Trailing net margin
10.7%
Indicated dividend yield
—

Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-11-04 (provider estimate, not issuer-confirmed).

Company background

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Company website

Q1 2026

Go beyond the headline.

PEN Stock: EPS Beats by 8% — Q1 2026 Earnings Analysis

Published 2026-04-23

Comparable businesses

PEN peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.

Market metrics · missing or inapplicable values shown as —
MetricPENPenumbra, Inc.Snapshot 2026-10-06Financial period: 2026-06-30
Market capMarket value, converted to USDUS$12.51B
Forward P/EProvider forward earnings estimate51.79x
EV / EBITDAEnterprise value / trailing EBITDA58.96x
Revenue growthLatest quarter vs prior-year quarter14.9%
Operating marginLatest reported quarter10.5%
Free cash flow yieldTrailing cash flow / market cap1.3%
Net debt / EBITDANet debt / trailing EBITDA-2.18x
Debt / equityTotal debt / positive book equity0.14x
Trailing P/ETrailing twelve-month earnings78.02x
Price / bookPrice / positive book equity per share8.17x
EV / salesEnterprise value / trailing revenue8.00x
Earnings growthLatest quarter vs prior-year quarter-23.5%
Gross marginTrailing twelve months67.8%
Net marginTrailing twelve months10.7%
Return on equityProvider trailing return; positive equity only11.4%
Free cash flow marginTrailing free cash flow / revenue10.7%
Dividend yieldIndicated annual dividend / price—
Earnings payoutProvider trailing dividend payout0.0%
Current ratioCurrent assets / current liabilities5.75x
BetaProvider historical market sensitivity0.70

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for PEN

All available reporting periods
Q1 20262026-04-23
Deep Dive2026-04-23

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.